Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of 3-Day IV Fosaprepitant for CINV in Pediatric Patients
NCT04054193Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2019
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 4 trial of fosaprepitant in chemotherapy-induced nausea and vomiting (CINV), sponsored by Merck & Co.. Started Sep 2019; status: completed.
02
Drugs
fosaprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT04054193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04054193.